News

The Swiss drug maker compared the efficacy and safety of Actemra monotherapy to the standard methotrexate treatment in rheumatoid arthritis patients. After 24 weeks of treatment, the Actemra

The FDA is now requesting results from a one-year safety trial on how the drug affects these organs. The decision stalls Wyeth’s plans to market Pristiq as the

This was the first of several regularly scheduled reviews by the data safety monitoring board (DSMB) that will occur over the duration of the trial. The purpose of

The randomized, double-blind, placebo-controlled trial, conducted with the company’s novel sustained release (SR) formulation of zonisamide paired with bupropion SR, evaluated various ratios of bupropion and zonisamide in

The company says ICA-105665 is an activator of subtypes of KCNQ ion channels, which are attractive targets for the treatment of epilepsy based on their function and genetic

The product was administered in once-daily doses in combination with an optimized ritonavir-boosted antiretroviral regimen. Vicriviroc is an extracellular inhibitor of HIV infection designed to block entry of

EntreMed received a no objection letter from the Therapeutic Products Directorate of Health Canada on its clinical trial application to conduct the clinical trial in leukemia patients. A

The trial will compare the efficacy and safety of peramivir administered intravenously once daily for five days versus oral oseltamivir administered twice daily for five days in adults

Target selectivity has the potential to significantly enhance efficacy of therapeutics while limiting their toxicity and side effects, therefore selectivity has long been the goal in the development